


PHARMACEUTICAL 2019

Synthetic Biologics Inc. Rank 183 of 371





PHARMACEUTICAL 2019

Synthetic Biologics Inc. Rank 183 of 371

The relative strengths and weaknesses of Synthetic Biologics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Synthetic Biologics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 166% points. The greatest weakness of Synthetic Biologics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -150%, being 181% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	29,511
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,384
Liabilities, Non-Current	0
Other Assets	23
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	302
Other Net Income	4,150
Property and Equipment	607
Research and Development	11,844
Revenues	0
Selling, General and Administrative Expense	5,727

Output Variable	Value in 1000 USD
Assets	30,141
Liabilities	3,686
Expenses	17,571
Stockholders Equity	26,455
Net Income	-13,421
Comprehensive Net Income	-13,421
Economic Capital Ratio	-150%